The IDH3G antibody targets the gamma subunit of isocitrate dehydrogenase 3 (IDH3), a key enzyme in the tricarboxylic acid (TCA) cycle. IDH3. located in mitochondria, catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate while reducing NAD⁺ to NADH, supporting cellular energy production. Unlike cancer-associated IDH1/2 mutations, IDH3 alterations are rare, but its dysregulation may contribute to metabolic disorders and mitochondrial dysfunction. The IDH3G subunit, encoded by the IDH3G gene, partners with IDH3α and IDH3β to form the functional heterotetrameric enzyme. IDH3G antibodies are vital tools for studying protein expression, localization, and interactions in normal and diseased tissues, particularly in research on metabolic syndromes, neurodegenerative diseases, or cancers linked to TCA cycle anomalies. These antibodies enable techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding in the exploration of IDH3's role in cellular metabolism and disease mechanisms. Their specificity helps distinguish IDH3 from other IDH isoforms, clarifying isoform-specific contributions to pathophysiology.